Deutsche Bank Cuts PT on Sanofi (SNY) – Here’s Why
Key takeaways
- Deutsche Bank Cuts PT on Sanofi (SNY) – Here’s Why Noor Ul Ain Rehman Sun, June 28, 2026 at 2:10 AM GMT+7 1 min read SAN.PA SNY Sanofi (NASDAQ:SNY) is one of the best low volatility stocks to buy under $50.
- Management further reported that Dupixent sales grew by 30.8% to €4.2 billion, suggesting a solid start to 2026.
- Sanofi (NASDAQ:SNY) researches, produces, and distributes pharmaceutical products.
Deutsche Bank Cuts PT on Sanofi (SNY) – Here’s Why Noor Ul Ain Rehman Sun, June 28, 2026 at 2:10 AM GMT+7 1 min read SAN.PA SNY Sanofi (NASDAQ:SNY) is one of the best low volatility stocks to buy under $50. Deutsche Bank cut the price target on Sanofi (NASDAQ:SNY) to EUR 95 from EUR 100 on June 15 and maintained a Buy rating on the shares. For reference, in its financial results for fiscal Q1 2026, Sanofi (NASDAQ:SNY) reported double-digit sales and business EPS growth. Fiscal Q1 sales growth was 13.6% at CER, while business earnings per share reached €1.88. Pharma launches sales rose by 49.6% and reached €1.2 billion, driven primarily by Ayvakit, ALTUVIIIO, and Sarclisa.
Management further reported that Dupixent sales grew by 30.8% to €4.2 billion, suggesting a solid start to 2026. Similarly, vaccine sales grew by 2.1% to €1.3 billion, benefiting from Heplisav-B. Sanofi (NASDAQ:SNY) also announced that Research and Development expenses reached €1.7 billion, up by 1.5%, while selling and general expenses reached €2.3 billion, up by 11.6%, primarily due to the effect of recent acquisitions.
Sanofi (NASDAQ:SNY) researches, produces, and distributes pharmaceutical products. The company's operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments.